|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
List of Ongoing Clinical Trials: Patient Summary
IBCSG 24-02
A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the
Role of Exemestane as the Adjuvant Therapies for Premenopausal Women with
Endocrine Responsive Breast Cancer
Summary
Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression
combined with hormone therapy using tamoxifen or exemestane may fight breast
cancer by reducing the production of estrogen. It is not yet known whether
suppression of ovarian function plus either tamoxifen or exemestane is more
effective than tamoxifen alone in preventing the recurrence of hormone-responsive
breast cancer.
This randomized phase III trial is studying ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.
Consent Form for Patients | Fast Fact Sheet